Background: Hidradenitis suppurativa (HS) is a chronic, inflammatory skin disease. Since current treatments are unsatisfactory for many patients, there is a high need for effective drugs for this debilitating disease. Recent pathogenic insights suggest inflammasome activation and IL-1β production are important in HS. Colchicine is efficacious in the IL-1β- and inflammasome-mediated diseases gout, familial Mediterranean fever and Behçet's disease, and therefore a potentially effective drug in HS. Objective: To investigate the efficacy of colchicine in HS. Methods: In an open prospective pilot study, 8 HS patients were treated with the accepted gout maintenance regimen of 0.5 mg colchicine b.i.d. orally up to 4 months. Efficacy was assessed by a physician global assessment. Results: Colchicine treatment did not result in a clinically relevant improvement of disease severity. Three patients experienced nausea and diarrhea as known side effects. Conclusion: Colchicine in the used dose regimen does not ameliorate HS severity. Copyright

Additional Metadata
Keywords Acne inversa, Behçet's disease, Familial Mediterranean fever, Gout, Hidradenitis suppurativa treatment, Inflammasome
Persistent URL dx.doi.org/10.1159/000332846, hdl.handle.net/1765/34139
Citation
van der Zee, H.H, & Prens, E.P. (2011). The anti-inflammatory drug colchicine lacks efficacy in hidradenitis suppurativa. Dermatology: international journal for clinical and investigative dermatology, 223(2), 169–173. doi:10.1159/000332846